To clarify the mechanism by which curdlan sulfate (CRDS) inhibits human immunodeficiency virus (HIV)-1 infection, we examined its influence on the binding of gp120 to CD4 molecules on T cells and macrophages, as well as on the production of TNF-a by gp120-stimulated macrophages (which promotes HIV-1 replication). CRDS treatment of cells not only inhibited the binding of HIV-1 gp120 to CD4+ cells, but also inhibited TNF-a production induced by gp120. Inhibition of HIV-1 infection by CRDS may be related to these two actions.

We report here that human immunodeficiency virus type 2 (HIV-2) envelope glycoprotein (gp105), but not HIV-1 gp120, can bind to CD8 molecules as well as to CD4 molecules on human T cells. This phenomenon may lead to differences in the life cycles of HIV-1 and HIV-2, and it may be related to the differences in disease manifestations of HIV-1 and HIV-2 infection, including longer survival of HIV-2-infected patients.

No abstract

We recently found that human immunodeficiency virus (HIV)-2 envelope glycoprotein, but not that of HIV-1, could bind to CD4 and CD8 molecules on T cells, and that the binding site of HIV-2 envelope glycoprotein was located on the alpha-chain (but not the beta-chain) of CD8. This study showed that the binding of HIV-2 envelope glycoprotein could induce phosphorylation of protein tyrosine kinase p56lck in CD8+ T cells. We also found that production of beta-chemokines in response to HIV-2 envelope glycoprotein was significantly higher than that in response to HIV-1 envelope glycoprotein, and that CD8+ T cells were the main source of beta-chemokines production among the T-cell population. These findings indicate the possibility that the binding of envelope glycoprotein to CD8 molecules are related to signal transduction into CD8+ T cells and the resultant beta-chemokine production in HIV-2 infection. Our results may help to explain the differences in disease manifestations between HIV-1 and HIV-2, including the lower virulence of HIV-2 and the longer survival of HIV-2-infected individuals.

No abstract